

POST-TEST

Consensus or Controversy? Clinical Investigators Provide Their Perspectives on Practical Issues and Research Questions in the Management of Non-Small Cell Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. In a study of afatinib (BIBW 2992) in combination with cetuximab for patients with NSCLC and disease progression on erlotinib or gefitinib, investigators reported confirmed responses in _____.
 - a. T790M mutation-positive disease
 - b. T790M mutation-negative disease
 - c. Both of the above
 - d. None of the above
2. Crizotinib is a targeted agent used in the treatment of ALK-positive NSCLC.
 - a. True
 - b. False
3. The results of the Phase II TREAT trial demonstrated that the combination of cisplatin and vinorelbine was better tolerated than cisplatin and pemetrexed for patients with early-stage NSCLC.
 - a. True
 - b. False
4. Results from the Lung Cancer Mutation Consortium demonstrated that _____ mutation is the most common single driver mutation found in lung adenocarcinoma.
 - a. K-ras
 - b. EGFR
 - c. PIK3CA
 - d. EML4-ALK